TY - JOUR
T1 - Women, lipids, and atherosclerotic cardiovascular disease
T2 - a call to action from the European Atherosclerosis Society
AU - Roeters Van Lennep, Jeanine E.
AU - Tokgözoǧlu, Lale S.
AU - Badimon, Lina
AU - Dumanski, Sandra M.
AU - Gulati, Martha
AU - Hess, Connie N.
AU - Holven, Kirsten B.
AU - Kavousi, Maryam
AU - Kaylkçloǧlu, Meral
AU - Lutgens, Esther
AU - Michos, Erin D.
AU - Prescott, Eva
AU - Stock, Jane K.
AU - Tybjaerg-Hansen, Anne
AU - Wermer, Marieke J.H.
AU - Benn, Marianne
N1 - Publisher Copyright:
© 2023 The Author(s).
PY - 2023/10/14
Y1 - 2023/10/14
N2 - Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease. Sex-specific factors, such as hypertensive disorders of pregnancy, premature menopause (especially primary ovarian insufficiency), and polycystic ovary syndrome are also relevant, with good evidence that these are associated with greater cardiovascular risk. This position statement from the European Atherosclerosis Society focuses on these factors, as well as sex-specific effects on lipids, including lipoprotein(a), over the life course in women which impact ASCVD risk. Women are also disproportionately impacted (in relative terms) by diabetes, chronic kidney disease, and auto-immune inflammatory disease. All these effects are compounded by sociocultural components related to gender. This panel stresses the need to identify and treat modifiable cardiovascular risk factors earlier in women, especially for those at risk due to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women.
AB - Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease. Sex-specific factors, such as hypertensive disorders of pregnancy, premature menopause (especially primary ovarian insufficiency), and polycystic ovary syndrome are also relevant, with good evidence that these are associated with greater cardiovascular risk. This position statement from the European Atherosclerosis Society focuses on these factors, as well as sex-specific effects on lipids, including lipoprotein(a), over the life course in women which impact ASCVD risk. Women are also disproportionately impacted (in relative terms) by diabetes, chronic kidney disease, and auto-immune inflammatory disease. All these effects are compounded by sociocultural components related to gender. This panel stresses the need to identify and treat modifiable cardiovascular risk factors earlier in women, especially for those at risk due to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women.
KW - Atherosclerotic cardiovascular disease
KW - Cholesterol
KW - Lipids
KW - Lipoprotein(a)
KW - Sex-specific risk
KW - Triglycerides
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=85170397650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170397650&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehad472
DO - 10.1093/eurheartj/ehad472
M3 - Review article
C2 - 37611089
AN - SCOPUS:85170397650
SN - 0195-668X
VL - 44
SP - 4157
EP - 4173
JO - European heart journal
JF - European heart journal
IS - 39
ER -